TrialSignal
Clinical trial intelligence report
A Phase IA/IB Study Evaluating TAS-116 in Patients With Advanced Solid Tumors
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT02965885-Jul 28, 2026
NCT ID
NCT02965885
Status
COMPLETED
Phase
PHASE1
Sponsor
Taiho Oncology, Inc.
Executive brief
Investment-Ready Snapshot
A Phase IA/IB Study Evaluating TAS-116 in Patients With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Taiho Oncology, Inc. in Advanced Solid Tumors. SEO and diligence focus: TAS-116, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02965885
Indication
Advanced Solid Tumors
Modality
small molecule
Target
TAS-116
Intervention
TAS-116
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.